Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
DURHAM, N.C., July 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...
-
DURHAM, N.C., June 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly...
-
DURHAM, N.C., June 27, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...
-
DURHAM, N.C., June 15, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...
-
Positive outcome triggers the second tranche of the Company’s previously announced financing agreement Argos Therapeutics to host conference call with the trial’s co-principal investigator,...
-
DURHAM, N.C., June 08, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...
-
- Entered into Equity Financing for Up to $60 million - - Phase 3 ADAPT trial of AGS-003 in Metastatic Renal Cell Carcinoma On Track for Upcoming Review by Independent Data Monitoring...
-
DURHAM, N.C., May 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...
-
DURHAM, N.C., May 05, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized...
-
DURHAM, N.C., April 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized...